Arca
Skip to content
Tools
Tools

ELANE: Neutrophil elastase

Serine protease that modifies the functions of natural killer cells, monocytes and granulocytes.

  • Drugs that act on it: 4
  • Approved: 1
  • In phases 1 to 3: 3
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on ELANE, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2
  • Protein or peptide 1
  • Other 1

Approved1

Phase 31

  • Sivelestat

Phase 22

  • Alvelestat
  • Depelestat

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Leukocyte elastase inhibitor.
    .alpha.1-proteinase inhibitor humanApprovedGrifolsProtein or peptideInhibitor6
    SivelestatPhase 3—Small moleculeInhibitor7
    AlvelestatPhase 2AstraZeneca PharmaceuticalsSmall moleculeInhibitor1
    DepelestatPhase 2—OtherInhibitor1

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 15 in all, from ClinicalTrials.gov.
    A Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460 in Adults With Emphysema Associated With Severe Alpha-1 Antitrypsin Deficiency (AATD).alpha.1-proteinase inhibitor humanPhase 1 / Phase 2RecruitingCRISPR TherapeuticsSep 30, 2026
    Safety and Efficacy Study of Sivelestat in Neuromyelitis Optica Spectrum DisorderSivelestatPhase 1 / Phase 2RecruitingKyushu UniversityJul 31, 2026
    A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD).alpha.1-proteinase inhibitor humanPhase 3RecruitingGrifols Therapeutics LLCApr 29, 2026
    Sivelestat Sodium as an Adjunct to Endovascular Thrombectomy for Acute Anterior Circulation Large-Vessel OcclusionSivelestatNot applicableRecruitingXuanwu Hospital, BeijingApr 27, 2026
    Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD).alpha.1-proteinase inhibitor humanPhase 4RecruitingCSL BehringJan 8, 2026
    Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic CoagulopathySivelestatPhase 2Not yet recruitingUniversity Hospital, Strasbourg, FranceOct 9, 2025
    Sivelestat Treatment for Postoperative Organ Protection in Type A Aortic DissectionSivelestatPhase 4RecruitingShanghai Zhongshan HospitalSep 5, 2025
    Intravenous Alpha-1 Antitrypsin for Hospitalized Patients With COPD Exacerbations (AECOPD Study).alpha.1-proteinase inhibitor humanPhase 2Not yet recruitingFondazione IRCCS Policlinico San Matteo di PaviaAug 15, 2025
    Study of Sivelestat Sodium in OPCABGSivelestatPhase 2RecruitingAffiliated Hospital of Nantong UniversityAug 12, 2025
    Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBCDepelestatPhase 2RecruitingVandana AbramsonJun 11, 2025
    Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket TrialSivelestatPhase 2RecruitingAssistance Publique - Hôpitaux de ParisApr 24, 2024
    Protective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery (PANDA VI)SivelestatNot applicableRecruitingNanjing Medical UniversityJan 8, 2024
    A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency.alpha.1-proteinase inhibitor humanPhase 1RecruitingKrystal Biotech, Inc.Sep 21, 2023
    Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency.alpha.1-proteinase inhibitor humanPhase 3Enrolling by invitationGrifols Therapeutics LLCJun 13, 2016
    Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell TransplantationAlvelestatPhase 1 / Phase 2Active, not recruitingNational Cancer Institute (NCI)Feb 1, 2016

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    • Cyclic hematopoiesis0.83
    • Neutropenia, severe congenital, 1, autosomal dominant0.83
    • Autosomal dominant severe congenital neutropenia0.67
    • Pulmonary emphysema0.56
    • Severe congenital neutropenia0.54
    • Autoinflammatory syndrome0.47
    • Acute myeloid leukemia with minimal differentiation0.46
    • Lung disorder0.41

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL248, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P08246, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.